第二十六屆中國國際醫藥(工業)展覽會暨技術交流會
API China 2022第88屆中國國際醫藥原料藥/中間體/包裝/設備交易會
展會時間:2022年05月10日-12日   展覽地點:青島    展館名稱:青島世博城國際展覽中心

《API China 咨訊》印度制藥企業欲通過產業鏈一體化,尋找中印合作最大公約數

According to a report from the Indian Medical Economics News, Dilip Surana, general manager of Microlabs, a leading export-oriented pharmaceutical company in India, pointed that the Indian pharmaceutical industry now has an excessive dependence on Chinese APIs.

Mr. Dilip Surana

來自《印度醫藥經濟信息》的報道稱,印度主要出口型制藥公司麥克羅( Micro labs)總經理迪利普·蘇拉納( Dilip Surana)在接受媒體采訪時指出,印度制藥業對中國的原料藥依然有巨大的依賴。

Dilip Surana said: " Since last year (2018), due to the increased supervision of China's environmental protection, the prices of some APIs and intermediates have skyrocketed, followed by frequent supply shortages. It has made huge influence in the market, not only in China but also in India. How to avoid the dilemma of the soaring price of APIs? Many Indian pharmaceutical companies, including Micro labs, have begun to find solutions.”

Dilip Surana表示:“自2018年以來,受中國環保治理監管力度加大影響,部分原料藥、中間體價格暴漲,隨之而來的是供應短缺頻繁的困擾。這些變化不僅對中國制藥產業影響巨大,并且對印度的制藥業也有強烈的沖擊。包括Mco在內的眾多印度制藥企業已著手策劃應對戰略?!?/span>

640.webp.jpg

Picture from in-Pharma Technologist


Indian pharmaceutical companies seek the "largest common denominator" of china-India cooperation


With further segmentation in the world pharmaceutical industry, the strategy to collect both upstream and downstream industry chain of pharmaceutical companies is valuable, but the cost is often too large to take with. The future approach is to establish a mutually beneficial and strategic cooperation supply chain with varied stakeholders.

隨著世界制藥工業分工愈來愈細,醫藥企業上下游產業鏈通吃策略雖然很有價值,但付出的成本往往也很大,前瞻的做法是與利益相關者建立互利共贏的戰略合作供應鏈關系。

640.webp (1).jpg
China and India, as the two largest producers and exporters of APIs in the world, have leading technologies and products respectively.
For example, China has strong market competitiveness in bulk fermentation, raw materials and chemical intermediates, while India has a comparative advantage in the production of high-efficiency chemical raw materials for some European and American generic drugs. It is vital for both parties to maintain a rational competitive relationship.
中國和印度作為全球兩個最大的原料藥生產和出口國,在各自優勢資源領域均有領先的技術和產品。例如中國在大宗發酵類原料藥和化學中間體的市場競爭力較強,而印度在一些歐美特色仿制藥所需高效化學原料藥的生產方面具有比較優勢,雙方保持理性的競合關系至關重要。

Picture from: Business Line

Driven by the strict national regulatory policies such as quality, environmental protection and safety, the industrial transformation and upgrading in China's API market has accelerated, and the company in market has improved its product quality and efficiency. As a result, the industry's competitive strength has rapidly increased.

中國原料藥市場在質量、環保、安全等國家監管政策趨嚴強化的推動下,產業轉型升級加快,企業提質增效增速,行業競爭實力增強。


At the same time, as an industry with an outward-looking competitive advantage, the internationalization strategy of APIs should be more stable in the future. Specifically, while abandoning the phenomenon of irregular competition in excessively low-priced exports, India and must adhere to the principle of mutual benefit for trading, focus on the fairness of transactions, follow the competition rules of complementary advantages to ensure market health.

與此同時,作為具有外向型競爭優勢的產業,原料藥國際化經營策略也宜更加穩健。具體來說就是,在擯棄過度壓價出口的不規范競爭現象的同時,要堅持誠信互利的貿易原則,關注交易公平性;遵循優勢互補的競爭規律,保證市場健康性。

640.webp (2).jpg
Picture from: Pharma IQ

It is imperative to strengthen international cooperation in the production of APIs, especially to find the largest common denominator in the cooperation of APIs in China and India, and to maximize the mutual promotion. This requires serving customers with a more rational attitude, developing a community to sharing market interests, and promoting sustainable cooperation upstream and downstream

加強原料藥產能國際合作已經勢在必行,特別是尋找中印兩國原料藥市場合作的最大公約數,對于實現互促作用最大化舉足輕重。這需要服務客戶更加理性,發展市場利益共同體,推進可持續合作

640.webp (6).jpg640.webp (4).jpg


The 83rd API China

As the leading exhibition in Chinese pharmaceutical industry, API China converges all related parties in China for policy & regulation interpretation, prictical experience education, product showing and market information press release. During more than 40 years' development, now it also bocomes a celebration for both Chinese pharamceutical enterprises and international ones. With its great influence in the industry, API China has been recognized as the one platform for supplier sourcing and information exchanging.

API China作為中國制藥行業的風向標,是中國制藥行業各方匯聚一堂,研習最新政策法規,分享國內外企業成功經驗,學習中國制藥行業最新產品動態,并了解中國制藥市場行業信息的極佳平臺。經過41年的不斷發展,API China現已成為國內外制藥行業在中國不可錯過的盛會。憑借其出色的行業服務水平與信息交換能力,API China成為了制藥企業在中國尋源并展開商務合作的圣地。尤其是在亞洲,更吸引了眾多來自印度、韓國、日本、東南亞的制藥企業前來參觀。




主辦單位:中國食品藥品國際交流中心
       2nhAvdk4SZW_-S4jNKxSLg_副本.png
        國藥勵展展覽有限責任公司
              2nhAvdk4SZW_-S4jNKxSLg_副本.jpg

  參展聯系:謝經理
  24小時熱線:18616981016(同微信)
  電話:
021-61200958
  郵箱:1054348312@qq.com
此網頁內容由展會資訊發布:非官網
在線聯系
 
 
 
 
 工作時間
周一至周五 :8:30-17:30
 聯系方式
24小時咨詢熱線:18616981016  謝(女士)